BioCentury
ARTICLE | Management Tracks

Domain, Initial among quartet of biotechs unveiling CEOs

Plus: Jim Jenson becomes CEO of Morphoceuticals, and updates from Xeno, NeoGenomics, DeepUll and Verastem

April 19, 2024 12:30 AM UTC

At least four biotechs unveiled new CEOs on Wednesday and Thursday, including a pair of well-funded, early-stage companies,  Domain Therapeutics S.A. and Initial Therapeutics Inc.

Sean MacDonald will lead Domain, which is targeting GPCR receptors. He became an adviser to the French company in February 2023 and took on the CBO role in January. ...